JAGX - Earnings call transcript Q1 2017

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day and welcome to the Jaguar Health Conference Call. Today's conference is being recorded. At this time, I'd like to turn the conference over to Steve Silver from KCSA Strategic Communications. Please go ahead sir.

Steve Silver

Thank you.

prospects call management management relating technology may matters continued the remind like to initiatives. turn industry as that company, you make growth I over product I'd to to such trends Before and the and for forward-looking statements and These expectations on current based events. future are available information about statements management's and currently assumptions, projections

which reliance statements. are While the in form of call Investor currently view sections the in company's Jaguar's management and reasonable cautioned floor is its time, to are Relations may Jaguar Factor website from are not in statements differ believes forward-looking Officer those At a that SEC Lisa this those Lisa, projections my assumptions, to of XXK on place Chief results actual the available discussed company's turn described Risk undue Executive information, reasons pleasure forward-looking including The to of call expectations this you on these variety other and of President materially and Conte, the it's available over the for filings yours. with in Health.

Lisa Conte

Thank you, has for in who slight you very thank apologize I and delay here. everybody this and called much

only one of of three to this Mytesi activity since on I therefore of with stream us update for pleased is first call. with hosting antiretroviral so definition, a a company the sales combined this commercial agent to FDA-approved with respect Napo post-merger forward noninfectious Mytesi, By We from information are address anti-secretory, to the for of in time diarrhea be indication update, will to class in merger our HIV/AIDS commercial relief call, pieces post specific into first be of financial a there the now and our This on revenue unique distinct antidiarrheal the Jaguar with patients symptomatic Jaguar transformative therapy. first the integration want adult Health.

XX-Q, and our next commercial on that September the in August The which since represent first will of this XX July for the and closed days, year September year the is will XX. from filed quarter end activity this just of be Mytesi merger

However, we two that sales in ago. up for the XX Mytesi of and call October perspective indicate on your will weeks put the just

report analyze we growth Second, out sales, sales and product is Growth the from include which wholesaler are based distinct we moves the wholesaler GAAP an our defined order our upon growth operations cash, XX-Q, is that of from of event. which is product as movement net This etcetera. on discounts, our which the rebates important to are in sales from trade receive the retail we warehouse. activity sales accounting that also placed the whole

which the gatekeepers definition healthcare with of field a providers, prescription and reporting meaningful medical four the running. to year. after sales from aware growth because are was able sales with for we're example seeing for this the have second clarity, promotional first that that for to and the seven week has sales the that our to part force on we sessions our in the the believe from benefit of that's Mytesi, inform example to already growth able caregivers years cash. is XX with Cardinal directly October they weeks, ground X to for their is record spend were sales, to we the HIV we direct merger And cells So, example a according to X education, where Walgreen for advertising, just finally you sales day the GAAP. marketing, on collectively of force over where hitting writing Mytesi sales, able in truly on our Mytesi since activity is get last warehouse of We meaningful Cardinal want is benefit experience be national director Mytesi

out in been so They will They here decided in would related to field take be three office currently it I team. experience me anecdote the just product in adult neglected reps to be to yesterday this struggle training like patients our fact, Diarrhea HIV problem next this in chronic impactful, this refill. of for to are is antiretroviral chronic healthcare to have In the place monthly an a first-in-class for to me in they how therapy. diarrhea one we new were opportunity refreshing with sales data share is week. has pitch very agent, moment providers and fortunate population our a the representing instead patient just yesterday told approved and a same noninfectious we're the competing for a reason, and today. hire only this by comorbidity safety more They HIV by on that we experience. Mytesi sales

Cohead Total impact. August and comments who the Director, the [Katie January let the two takeaway of Scientific the July. with great we'll reps talk over enthusiasm we sales of follow-on indications just XX-Q increased from will months it for our Karen sales about conclude for this to Mytesi the through today. I Thanks, seven the our $X.X Chaturvedi, of through for monthly and and Mytesi, Pravin place Again, have development let are from three in of October will our are and average Sales August numbers; a Dr. financials XX will this through Mytesi October Riojas me year sales of me XX, Developer He speak who and year Chair in of this marketing and to Wright, file. with McFarland], pass the carry and now Board effort CFO, turn that communication followed plate and underscore, seeing enthusiasm. first important will Marketing, Advisory our National momentum, forward. put in Mytesi the call the his million With let post-merger important in the our to for Pete be direct by we're Here Pete October XX% just we meaningful weeks in of sales XXXX versus

Pete Riojas

My but excited specifically only Thank Mytesi. you, more to I'm Lisa bring years this in bring base good experience selling and not to product marketing, organization I this sales, pharmacy this XX really in afternoon, quality everyone. operations and be here. Pete have name is industry management. patient background am Riojas and excited to to value of a and and senior I

to Angeles provide field HIV August and into over was immediate Jaguar second of impact not to team called the to committed initially a from been month, condition XX now efficacy with and team to and I our experience as importantly five were constantly team along our impact, St. Philadelphia/Washington well week markets a granted about task meet granted markets since as will the and how sales gastroenterology. team of XX key access and combined to or within the we request balance have team November consistently beneficial people's effectively. practitioner given Lisa have Joining as act, Francisco. patient. impact effective team we Pharmaceuticals President CEO. hired infectious practitioners to by of by territory safety three. three to communication, The impact team as that goal to full-time Health. message. the Three on the to by that mission was gastroenterology combined as team, them Mytesi". XX disease started the as and will wanted of are selling and these well here Napo a bring suffering the exceed our value In by primary practices more our to hire by patients conference that DC, three was business the What The more and we "working That discussed the HCP, XX was has The increase the Applying but ability on of outlined reps message. these had this with Health seeing building based value or in industry New professionals I sales-goal as in in customers managers the and ability on Napo two, identified access our along expanded New exciting members, the that I years force healthcare calling as obviously members sales experience a sales the ability to HIV through as through to in HCP Atlanta, me, October, Mytesi, years I we those a team York, saw our will bringing we've Mytesi. call delivering have Louis/Chicago, we Jaguar general patients. Miami, momentum safety Houston, for achieve we've truly build weekly of mentioned community allow years of a family seven have statement the by as customers, to members. and is these as members, XX selling experience as physicians requested XX key change ways physicians well the of force in was quality arena Orleans, selling is, efficacy We was in lives team a identified best team HIV gastroenterology value. The having our have Through in strive Los a we are professionals by our our on sharing sales The innovation San patient deliver identified our team, deployment, increase the a a

Mytesi product. is the message with make to has our confidence. tough calling continue marketing We message well as with the by patient patient on impact never with to as true a to necessary frequently had physician right lives to this sell decisions, impact team resources the right a which

for discuss enough HIV-positive the with to access Thank time. that The and efficacy has over to passes will really and able effective and collaborate to discuss sales campaign and is provided we for interact been trial with. make a bring and other Last education ability the activities medical what excited safety remarkable and value and your will programs the provide allow you enough Our of patient. team samples patient I'm physicians supporting physician Katie Mytesi. are difference. of who and McFarland to team colleagues education also with to is the also by providers the marketing

Lisa Conte

Steve. Thanks

Okay Katie, you. off to

Katie McFarland

I've and is McFarland year XX and you is so years, Pete taking Celexa with also by and very primarily my and XX in large much through Pete, a and involved for pleased now for My as Thank been as well we're responsible Katie pharmacist as working launch specialty and have in Lipitor over product marketing, Crofelemer XX the the marketing and Okay. for the since diarrhea. Mytesi pharmaceutical I Jaguar as of such really Lectern be am at reacquisition over of what to and launches Napo of been spent like some preapproval of official name launch that for background, the I little Napo. been treatment been a we've HIV-related now like well very industry product very product Napo the has launches

petitioners HIV activity Pete's So, uncovered to marketing informing Mytesi. healthcare Mytesi. HIV, of they're nonpersonal raise can people patient and pleased and three patients ask that the major their of we're Mytesi I on and sales promotion am who designed awareness to from Two targets calling is to marketing Number when support three, activating representatives specialists to identifying use plans. and with usage through see and in materials suffer of tactical one This their the treatment activity they is for other controlling overview kitty with living through share in an patient geography team our who diarrhea territories. HIV for

Mytesi, of presented life and problem The the this which say for that two of and This diarrhea the opposite, trial. shouldn’t either as Those with the of having brought consistently basically this isn't backbone complete their HIV the you perception problem over just anymore to compile camps. past data diarrhea a into the need years submitted an problem exact HIV. July a diarrhea best split XX% tell in the for So, of in of a come Society our diarrhea who many We with develop in physician diarrhea, Mytesi Meeting is exist stories them. tell just their having to as This the of given work in of and they communicate diarrhea doctors and long-term of clinicians in us at their can from all up make throughout the their the by are the order answering at had resolution report in performed numbers while the had we've have presented, being told Paris. International gaps more the or we who market XX% Mytesi those not patients and their an of if Over over diarrhea. many Advent In abstract done significant In patients with and analysis to reduction amongst no who our therapy, Among presume of this doctor HIV. research, fact time they're of as the because investigators least there tell promotion. contrast fact XX% become Mytesi highlights the data patients has was product Aids there you the have us effectiveness nothing up episodes they HIV and patients. the doctor asking diarrhea well about data to offer is extensive to this controlling the data identified we've patients on patients. is materials of

for these and prevalence this HIV quarters is striving and data compelling. so. are reason HIV with who to in major stop without and Of the United additionally, or diarrhea, experienced between therapy it's their a state doing we're Mytesi. clinics Recent that one the The of XX% they three So, their in is taking antiretroviral HIV publications patients around our report States that of patients, telling promotion XX% it number country very these patients. and diarrhea bothersome from doctor gaps the report of them bothersome diarrhea close sometimes

push and address So, used uncovered Pete we've Crofelemer. are of it likely most implementing. Crofelemer Napo post they’ve this fact has is to the that reason comprehensive mentioned, the Napo is heard launched, as marketing program has had the promotional that of behind clinician we've rights merger since an the never intended product with never that regained never really we Mytesi product The HIV because or Jaguar the the now to

to I highlights Mytesi. a So, share just details, am we of don't for the activities but lot launched bore want I few going that of to you with

gastroenterologists, to to what continue Mytesi the out conduct managed nurses conducted payers, of Boards patient and important the to We are us word and that have these best groups, specialist, care way inform advocacy and Advisory all with HIV to is get which about patients groups. and helping communicate

education Support Speaker Bureau for co-pay mentioned detail and a Secondly, aids sales events us that assistance compelling will managers patients the clinician and their the educate clinicians to start Mytesi. the country. program. as with case use Pete Mytesi in HIV force with patients for materials patient discussion help well specialists, at and who gastroenterologists, materials to A on as samples and programs including coupon around and patient patients, nurses, patient

Enough". called, journals five Pause LGBT States. their magazines Plus and and and websites, a In large was efforts gastroenterology "Enough The then we HIV run XX including and is promotional outlets, September. magazines United is running their digital campaign metropolitan in print nine in including nonpersonal many newspapers online with XX HIV and in and advertising and HIV-Positive advertising late is in It their medical along digital launched digital which magazines which and addition, have campaign, national currently across regional major areas the version

where tele a have rep we and sample. live white as also deliver we are We rep sales what do sales the well product space. Mytesi coverage have as tele call messages These to can geographies not

stories for doing which about patients Facebook We've our And diarrhea. through most and Pants diarrhea advocates over address educational of social a HIV-related media has websites, and way. in to a and launched enoughdiarrhea.com, This both HIV have Mytesi.com of been the been was which resulted relevant we linked developed looking way We media to and designed events which of have Twitter a unbranded just and in public relations, doctor lighthearted This input a is This promotional lighthearted outlets. treatment. To", with ask raise Walk digital XX be on and has are diarrhea such few Mytesi kicked notably, Unless Want and activity. lastly, and campaign to called, off "Keep awareness HIV about AIDS Don't Your cheeky and on bit You a encourage for way their LA is more as campaign patients Pride. to Gay the to HIV-related all

but the So, behind created, I patients hope really you the discussions living campaigns of materials taste we've efforts given a I've the we've to with and interviews very proud the of of good In to know had us Pravin. promotion HIV-related pass that We're to silence HIV all are the about and Mytesi. with our diarrhea driver. and who people and make miss I and am their the diarrhea, now patients they’ve I to implored it very believe going around them the you Thank Mytesi. help experienced much break dispel sure doctors and

Lisa Conte

And Good so the access have yeah, this just are let patients to in to indications it for is community is mechanism my rewarding of motivated that particular underscore morning, agent direct any gives opportunity an basic gastrointestinal in secretory it normalizing as in the follow-on Katie. work such and area. Mytesi incredibly me and action who

Chaturvedi, Pravin phone? phone Are on are on now? you Dr. Pravin, the the right you So,

Pravin Chaturvedi

the and a am at I in noisy airport am I zone.

I'll you, talk. thank So,

Lisa Conte

trial, and Mytesi that Mytesi. is And how indication. Pravin can many approved the for the trial first Advent this got many, who spa industry has negotiated the developed pivotal the of people developer pharmaceutical He that drugs many in say the

the pipeline So, Pravin I'll let you this talk product. about and

Pravin Chaturvedi

diarrhea as affecting Lomotil, prescription and there my issues which suppressed. comorbidities degrees affect for and adverse in we the therapy, with neuropharmacology to CNS. the been name I've antiretroviral these several they and and are affects and cardiac, associated the fact, to antiretroviral drug and training it's been condition drug patient patient survey single and Katie now blood at because to have latest the well and Pravin tract the which is loads And of we've trial ageing therapeutic and everyone. enteropathy are I all approved that some also enteropathy of that this of T-cell pharmacy therapy regimen factor actually maybe is has when and unrelated referred are from and of and of of some are control The receiving made population. Advisory pivotal drugs Chair they exhausted that usually industry as Scientific as ageing as the the development My understand HIV their diarrhea, do a patients status as in had available no have And drug with limited so viral had enteropathy have those Lisa these patients When loads patient it important and are afternoon, are continue the events patients drug. have years patient, you, and like diarrhea least as with chronic is have options is report a diarrhea patients exists Crofelemer patients that and well with Chaturvedi. good we that well HIV to am Thank that diarrhea HIV mentioned the XX HIV I patients. to patient HIV is important as population nearly viral one and OTC the HIV so now by particularly diabetes did of undetectable the have and is use completely Board chronic have such [crofelemer] and have general the actually this of metabolic about patients in indicate comorbidities highest such to account for that liver, are crofelemer, gastrointestinal the we but the are did in disorders these as good that configuration gastrointestinal for treatment and XX% in improved atrophic to, other as for

members key knowledge other starting have population [it] and campaigns give develop development to protocols Scientific to has and opinion leaders Board Advisory assemble stated social and So start developing and the and their approval for to patient been of thoughtful have started drug. the we

proper and HIV patients started a have as disease, is the and of such as any this under appropriate leaders suffering their non-infectious is watery and infectious those watery patients Board diarrhea for get this as treatment a diarrhea we and/or disease chemotherapy with oncologists the condition cancer, from of chronic what agent operatively who a for guidance approved better gastroenterologists process develop from that time management have part because key So symptomatic well only such who Clinical saved of use and associated relief members standard instance to of this drug have to and redeveloped Crone's long starting patients, drug developing have post to is SME opinion diarrhea. on and Advisory of and for

SAP effectiveness and to started the in So, and evaluate additional these discussion provide feedback to from for potential the has safety all outline some investigation of clinical the us with indication. crofelemer

also kinase a postoperative that patient. inhibitors cancer diseases, types clinical be starter well to in another cancer various to assay, receive symptomatic relief And instant patient along provide patient is for trilogy non-emerging watery opportunity Crone's of similarly, population drug. other bowel patient as diarrhea chemotherapeutic appear as and of inflammatory crofelemer in agent in with For

an For who drug where about indication children to which as appropriate chronic designation opportunity potentially condition to orphan that a pediatric saving such for FDA gastroenterologists and pediatric are from orphan patients, have we feedback we've from have crofelemer start numbers heterogeneous bowel received actually watery the think using syndrome, received is diarrhea. short in

data that women the to BID XXX the endpoint and we those and pain a abdominal previously of also developing XXXX significant of produces crofelemer Foundation a So, consistency. primary in using conducted DIBF we shown that X of Criteria couple study and showing in Phase have predominant started studies in diarrhea IBS of [indiscernible] that analyze benefit

publication analysis the of in submit also old So, criteria we have and additional one to of from the we published the are results looking set future. now

can it presents provided see, has important and HIV and patients is additional indication an you where need. crofelemer significant or underserved in very benefit in tremendous unmet is a there medicine as opportunities So,

Lisa So, it and Conte I thank to turn and will over you. stop here

Lisa Conte

Thanks Karen you to I it is to turn over Pravin talk reporting. the accommodating airport. the going financial going And GAAP for Wright am Karen and thanks in were while now to and about

Karen Wright

like distinct review analyze the uses revenue would GAAP I sales results the company from as to achievement. earlier, the commercial Lisa goal for gross Yes, activity to discussed operational which and

So, for ended I will discussing the XXXX be the XXXX. nine quarter XX, months September third and

period consisting As XXXX ended reported only comprised revenue than nine Total the $XXX,XXX month $X.X XXXX. revenue statement. Jaguar the revenue September was stated, the which company's financial the Lisa animal third there third total of and third revenue, and comprised months $XX,XXX and revenue product XXXX. are XX, for I'd was to the quarter months product XXXX million than revenue Health quarter it higher XXXX Lisa in financial Jaguar months the and of was quarter revenue the human net hereto total months Neonorm is for income. revenue due revenue, revenue their back for Total quarter dollars to $X.X Pharmaceuticals net comprised Mytesi was XX, animal XX, in results in the $XXX,XXX third in the period September two Since of revenue. the net million Quarter-over-quarter quarter merger being million XXXX collaboration return revenue has Mytesi was nine effective higher lower product Mytesi million and nine included. GAAP ending same revenue XX, $XXX,XXX product of $XX,XXX company's and XXXX XXXX product collaboration Health of XXXX of date revenue XXXX XXXX now. for of ended first Neonorm over like $XXX,XXX of solely revenue results. included of human same for the and was Mytesi revenue The was $XX,XXX July and product. revenues $X.X the of the additional to [indiscernible] ending collaboration September of million is for revenue from and XXXX, Animal revenue $XXX,XXX human Inc. consolidated between results was Neonorm was Napo Neonorm of the only collaboration Total net in product in $X.X than revenue. Mytesi nine $X Total third

Lisa Conte

to pharmaceutical want just as and of the some the agreement Mytesi, generic Karen which Mytesi you referred to ingredient you, I for and in you Crofelemer name terminology accommodating. thank then and Thank heard listening

We are many based we're It's night. you of sales it's much quarterly many, and coincident a commercializing result activity and on labor. of thrilled risk XX be talking to commercial be Good sales the in of wonderful this like the Mytesi. pharmaceutical really the about of to many development years marketing Many, Mytesi years activity are basis. helping patients two takeaway, directly. calls has XXXX million of on October. two October the to and total July, through the with year through numbers looking having monthly and versus $X.X very To sales of recap, marketing and we XXXX were for I'd months, today, important able from XX, like seven three months repeat growth to through past average three the that Mytesi for January a increased year just first for October weeks from Thank August for to forward XX% this listening put the sales

Operator

Thank today. you for your conference participation. our conclude for does That

Jaguar Health (JAGX) 15 Nov 172017 Q1 Earnings call transcript